Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Verve Therapeutics Inc Stock Research

VERV

11.72USD-1.54(-11.61%)Market Closed
Watchlist

Market Summary

USD11.72-1.54
Market Closed
-11.61%

VERV Stock Price

VERV RSI Chart

VERV Valuation

Market Cap

823.0M

Price/Earnings (Trailing)

-4.28

Price/Sales (Trailing)

151.34

EV/EBITDA

-3.57

Price/Free Cashflow

-4.76

VERV Price/Sales (Trailing)

VERV Profitability

EBT Margin

-3527.67%

Return on Equity

-35.17%

Return on Assets

-28.25%

Free Cashflow Yield

-20.99%

VERV Fundamentals

VERV Revenue

Revenue (TTM)

5.4M

Revenue Q/Q

49.07%

VERV Earnings

Earnings (TTM)

-192.2M

Earnings Y/Y

-31.84%

Earnings Q/Q

-3.86%

Price Action

52 Week Range

11.2540.88
(Low)(High)

Last 7 days

9.7%

Last 30 days

1.1%

Last 90 days

-29.3%

Trailing 12 Months

-61.2%

VERV Financial Health

Current Ratio

15.43

VERV Investor Care

Shares Dilution (1Y)

27.51%

Diluted EPS (TTM)

-3.15

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for VERV

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-12-14
Bellinger Andrew
acquired
103,320
2.87
36,000
cso & cmo
2022-12-01
Bellinger Andrew
sold
-19,851
22.95
-865
cso & cmo
2022-11-29
Dorval Allison
acquired
-
-
1,875
chief financial officer
2022-11-29
Dorval Allison
sold
-12,243
22.1
-554
chief financial officer
2022-11-04
GV 2017 GP, L.L.C.
sold
-1,512,810
31.1386
-48,583
-
2022-11-04
Yeshwant Krishna
sold
-1,512,810
31.1386
-48,583
-
2022-11-04
Yeshwant Krishna
sold
-
-
-48,583
-
2022-11-04
GV 2017 GP, L.L.C.
sold
-1,512,800
31.1386
-48,583
-
2022-11-04
GV 2017 GP, L.L.C.
sold
-
-
-48,583
-
2022-11-03
GV 2017 GP, L.L.C.
sold
-
-
-49,569
-

1–10 of 50

Which funds bought or sold VERV recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-21
Jefferies Group LLC
new
-
430,921
430,921
-%
2023-09-20
BARCLAYS PLC
added
11.46
706,000
2,275,000
-%
2023-08-21
OSAIC HOLDINGS, INC.
reduced
-1.45
3,912
17,811
-%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
10.78
299,503
979,406
-%
2023-08-16
Nuveen Asset Management, LLC
added
9.44
980,201
3,298,200
-%
2023-08-15
GOLDMAN SACHS GROUP INC
added
1.57
1,216,080
5,007,710
-%
2023-08-15
LAZARD ASSET MANAGEMENT LLC
added
2.94
9,000
35,000
-%
2023-08-15
WELLS FARGO & COMPANY/MN
added
14.93
375,124
1,133,830
-%
2023-08-15
ALLIANCEBERNSTEIN L.P.
reduced
-3.94
282,950
1,418,810
-%
2023-08-14
IFP Advisors, Inc
new
-
304
304
-%

1–10 of 46

Latest Funds Activity

Are funds buying VERV calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own VERV
No. of Funds

Schedule 13G FIlings of Verve Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
singer james r
8.1%
5e+06
SC 13G/A
Feb 14, 2023
casdin capital, llc
3.7%
2,290,571
SC 13G/A
Feb 13, 2023
arch venture fund x, l.p.
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
6.19%
3,812,024
SC 13G
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 07, 2023
state street corp
7.26%
4,471,049
SC 13G
Feb 06, 2023
wellington management group llp
1.39%
859,102
SC 13G/A
Feb 14, 2022
gv 2017, l.p.
13.12%
6,320,905
SC 13G
Feb 14, 2022
casdin capital, llc
6.5%
3,138,167
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A

Recent SEC filings of Verve Therapeutics

View All Filings
Date Filed Form Type Document
Sep 19, 2023
4
Insider Trading
Sep 19, 2023
3
Insider Trading
Aug 10, 2023
8-K
Current Report
Aug 10, 2023
10-Q
Quarterly Report

Verve Therapeutics News

Best Stocks
Teacher Retirement System of Texas Reduces Holdings in Arista ....
Best Stocks,
14 hours ago
Investing.com UK
The Motley Fool
GuruFocus.com
ETF Trends
Investor's Business Daily
8 Big Stock Disasters Knock Cathie Wood Off Her Perch.
Investor's Business Daily,
45 days ago

Returns for VERV

Cumulative Returns on VERV

Risks for VERV

What is the probability of a big loss on VERV?

88.3%


Probability that Verve Therapeutics stock will be more than 20% underwater in next one year

88.3%


Probability that Verve Therapeutics stock will be more than 30% underwater in next one year.

86.7%


Probability that Verve Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does VERV drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Verve Therapeutics was unfortunately bought at previous high price.

Drawdowns

Financials for Verve Therapeutics

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q2
Revenue47.4%5,438,0003,689,5001,941,000--
Operating Expenses9.5%213,850,000195,366,000167,628,000151,446,000130,159,000
  S&GA Expenses10.2%46,999,00042,650,00037,533,00032,695,00029,110,000
  R&D Expenses9.3%166,851,000152,716,000130,095,000118,751,000101,049,000
EBITDA100.0%--153,917,000-154,530,000--
EBITDA Margin100.0%--34.51-79.61--
Earnings Before Taxes-Infinity%-215,228,000--157,334,000--163,784,000
EBT Margin100.0%--35.28-81.06--
Net Income-7.3%-192,233,000-179,196,000-157,387,000-147,639,000-125,198,000
Net Income Margin100.0%--40.18-81.09-39.73-
Free Cashflow100.0%--151,620,000-135,564,000-126,728,000-117,273,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22020Q4
Assets-7.1%58963467967332434938441142778.00
  Current Assets-8.6%47351856356229932936739442074.00
    Cash Equivalents-16.4%70.0084.0011527773.0091.0070.001483879.00
  Net PPE0.9%21.0021.0019.0015.0012.0011.007.007.006.004.00
Liabilities-0.8%12412512812528.0018.0027.0026.0021.0017.00
  Current Liabilities-1.6%33.0034.0035.0029.0026.0015.0022.0020.009.007.00
Shareholder's Equity-8.7%465509551548296331357385405-
  Retained Earnings-13.6%-450-396-344-303-257-217-186-155-132-66.54
  Additional Paid-In Capital1.1%9169068968525555495445405383.00
Shares Outstanding0.3%62.0062.0062.0060.0049.0049.0049.0048.008.003.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22019Q4
Cashflow From Operations-15.4%-159-137-122-117-109-96.25-77.88-64.81-49.78-48.59-35.26-25.30-27.93-7.44
  Share Based Compensation12.8%30.0026.0022.0019.0015.0011.007.005.003.002.001.001.000.000.00
Cashflow From Investing12.6%-175-200-155-44.63-201-190-239-17039.0028.00-51.13-10.87-120-12.76
Cashflow From Financing0.2%3313303292911.0028437737637712593.00-18518.00

VERV Income Statement

2023-06-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Collaboration Revenue$ 2,093$ 0$ 3,497$ 0
Operating expenses:    
Research and development47,26033,12594,37057,614
General and administrative13,4169,06725,96916,503
Total operating expenses60,67642,192120,33974,117
Loss from operations(58,583)(42,192)(116,842)(74,117)
Other (expense) income:    
Change in fair value of success payment liability(662)938762,615
Interest and other income, net5,43830810,984390
Total other income, net4,7761,24611,0603,005
Loss before provision for income taxes(53,807)(40,946)(105,782)(71,112)
Provision for income taxes(176)0(176)0
Net loss$ (53,983)$ (40,946)$ (105,958)$ (71,112)
Net loss per common share attributable to common stockholders, basic$ (0.87)$ (0.84)$ (1.71)$ (1.46)
Net loss per common share attributable to common stockholders, diluted$ (0.87)$ (0.84)$ (1.71)$ (1.46)
Weighted-average common shares used in net loss per share attributable to common stockholders, basic61,953,99248,674,87361,871,15848,623,330
Weighted-average common shares used in net loss per share attributable to common stockholders, diluted61,953,99248,674,87361,871,15848,623,330
Comprehensive Loss:    
Net loss$ (53,983)$ (40,946)$ (105,958)$ (71,112)
Other comprehensive income (loss):    
Unrealized income (loss) on marketable securities(517)(206)(60)(710)
Comprehensive loss$ (54,500)$ (41,152)$ (106,018)$ (71,822)

VERV Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 70,042$ 115,412
Marketable securities392,434439,396
Collaboration receivable2,0931,012
Prepaid expenses and other current assets8,4977,339
Total current assets473,066563,159
Property and equipment, net21,25218,778
Restricted cash4,8244,824
Operating lease right-of-use assets88,76691,877
Other long term assets1,223585
Total assets589,131679,223
Current liabilities:  
Accounts payable3,1462,424
Accrued expenses19,83920,767
Lease liability, current portion10,04611,904
Total current liabilities33,03135,095
Long-term lease liability67,81970,014
Success Payment Liability2,8092,885
Deferred revenue non-current20,01420,014
Other long term liabilities236283
Total liabilities123,909128,291
Commitments and contingencies (See Note 7 and Note 8)
Stockholders' equity:  
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding00
Common stock, $0.001 par value; 200,000,000 shares authorized, 62,064,279 and 61,730,816 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively6262
Additional paid-in capital916,109895,801
Accumulated other comprehensive loss(754)(694)
Accumulated deficit(450,195)(344,237)
Total stockholders equity465,222550,932
Total liabilities and stockholders' equity$ 589,131$ 679,223
Sekar Kathiresan
110
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.